References
- Bursa Osmangazi'de Bonzai Kullanan Tugay Temiz İsimli Genç Ölü Bulundu. Canli Haber. 2014. [cited 2014 Aug 12]. Available from: http://www.canlihaber.com/bursa-osmangazide-bonzai-kullanan-tugay-temiz-isimli-gencolu-bulundu-18740h.htm.
- Sozal B. Bonzai iki can aldı. Sabah. 2014. [cited 2014 Sep 20]. Available from: http://www.sabah.com.tr/yasam/2014/06/24/bonzai-iki-can-aldi.
- Eğilmez M. Gençlere yeni tuzak: Bonzai. Aljazeera. [cited 2014 Aug 12].2014. Available from: http://www.aljazeera.com.tr/al-jazeera-ozel/genclere-yeni-tuzak-bonzai.
- Acil servislerde bonzai patlaması. Radikal. 2014. [cited 2014 Oct 15].Available from: http://www.radikal.com.tr/saglik/acil_servislerde_bonzai_patlamasi-1208815.
- World Drug Report. United Nations Office on Drugs and Crime (UNODC), Vienna, 2012. [cited 2014 Aug 18]. Available from: https://www.unodc.org/documents/data-and-analysis/WDR2012/WDR_2012_web_small.pdf
- Welch SP. The Pharmacology of Cannabinoids. In: Ries RK, Miller SC, Fiellin DA, Saitz A, (editors). Principles of Addiction Medicine. Philadelphia: LWW; 2009. p. 193–214.
- Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004;47(Suppl 1):345–58. [CrossRef]
- Understanding the ‘Spice’ phenomenon: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2012. Available from: http://www.emcdda.europa.eu/attachements.cfm/att_80086_EN_Spice%20Thematic%20paper%20—%20final%20version.pdf.
- Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Delta(9)-THC: mechanism underlying greater toxicity? Life sciences 2014;97(1):45–54. [CrossRef]
- Cohen J, Morrison S, Greenberg J, Saidinejad M. Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics 2012;129(4):e1064-7. [CrossRef]
- Mechoulam R, Feigenbaum JJ, Lander N, Segal M, Jarbe TU, Hiltunen AJ, et al. Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 1988;44(9):762–4. [CrossRef]
- Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. The Journal of neuroscience: the official journal of the Society for Neuroscience 2005;25(8):1904–13. [CrossRef]
- Lindigkeit R, Boehme A, Eiserloh I, Luebbecke M, Wiggermann M, Ernst L, et al. Spice: a never ending story? Forensic science international 2009;191(1–3):58–63. [CrossRef]
- Grim R. K2 Crackdown: DEA Using Emergency Powers To Ban Fake Pot. The Huffington Post. 2010 November 24, 2010. Available from: http://www.huffingtonpost.com/2010/11/24/dea-using-emergency-power_n_788149.html
- Haiken M. “Spice” and “K2” vs. “Bath Salts”: The Other Designer Drug Scare. Forbes 2012. Available from: http://www.forbes.com/sites/melaniehaiken/2012/06/13/spice-vs-bath-salts-the-other-designer-drug-scare/2/
- Synthetic Drug Abuse Prevention: Addition of synthetic drugs to schedule I of the Controlled Substances Act 2012. Available from: https://www.govtrack.us/congress/bills/112/s3190/text.
- Huffman JW. The search for selective ligands for the CB2 receptor. Current pharmaceutical design 2000;6(13):1323–37. [CrossRef]
- EMCDDA 2013 Ulusal Raporu: Turkish Monitoring Centre for Drugs and Drug Addiction (TUBİM); 2013. Available from: http://www.kom.pol.tr/tubim/SiteAssets/Sayfalar/Türkiye-Uyuşturucu-Raporu/2013(TÜRKÇE).pdf.
- Notes from the field: severe illness associated with reported use of synthetic marijuana—Colorado, August-September 2013: Centers for Disease, Control Prevention (CDC); 2013 [1016-7]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24336136.
- Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug and alcohol dependence 2011;117(2–3):152–7. [CrossRef]
- Drug Abuse Warning Network (DAWN) Report: Substance Abuse and Mental Health Services Administration (SAMHSA); 2012. Available from: http://www.samhsa.gov/data/2k12/DAWN096/SR096EDHighlights2010.pdf.
- Siefer T. New Hampshire declares state of emergency over synthetic drug. Reuter. 2014. Available from: http://www.reuters.com/article/2014/08/14/us-usa-new-hampshire-drugs-idUSKBN0GE2AK20140814
- Synthetic Marijuana: The American Association of Poison Control Centers (AAPCC) 2014. Available from: www.aapcc.org/alerts/synthetic-marijuana.
- Spice (“Synthetic Marijuana”). National Institute of Drug Abuse (NIDA); 2012. Available from: http://www.drugabuse.gov/publications/drugfacts/spice-synthetic-marijuana
- Caviness CM, Tzilos G, Anderson BJ, Stein MD. Synthetic Cannabinoids: Use and predictors in a Community Sample of Young Adults. Substance Abuse: official publication of the Association for Medical Education and Research in Substance Abuse. 2014 Sep 15:0 [Epub ahead of print].
- Wohlfarth A, Scheidweiler KB, Castaneto M, Gandhi AS, Desrosiers NA, Klette KL, et al. Urinary prevalence, metabolite detection rates, temporal patterns and evaluation of suitable LC-MS/MS targets to document synthetic cannabinoid intake in US military urine specimens. Clin Chem Lab Med. 2014 Sep 27. [Epub ahead of print. [CrossRef]
- Forrester MB, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid and marijuana exposures reported to poison centers. Human & experimental toxicology 2012;31(10):1006–11. [CrossRef]
- Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life sciences 2005;78(5):539–48. [CrossRef]
- Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational psychiatry 2012;2:e94.
- Tellioglu T, Tellioglu Z. Can medical marijuana be used in the treatment of psychiatric disorders? Klinik Psikofarmakoloji Bulteni—Bulletin of Clinical Psychopharmacology 2012;22(1):98–109. [CrossRef]
- Rominger A, Cumming P, Xiong G, Koller G, Forster S, Zwergal A, et al. Effects of acute detoxification of the herbal blend ‘Spice Gold’ on dopamine D2/3 receptor availability: a [18F]fallypride PET study. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 2013;23(11):1606–10. [CrossRef]
- Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of “spice gold”. Deutsches Arzteblatt international 2009;106(27):464–7.
- Bhanushali GK, Jain G, Fatima H, Leisch LJ, Thornley-Brown D. AKI associated with synthetic cannabinoids: a case series. Clinical journal of the American Society of Nephrology: CJASN 2013;8(4):523–6. [CrossRef]
- Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011;128(6):e1622–7.
- Freeman MJ, Rose DZ, Myers MA, Gooch CL, Bozeman AC, Burgin WS. Ischemic stroke after use of the synthetic marijuana “spice”. Neurology 2013;81(24):2090–3. [CrossRef]
- Ozturk E, Oral A, Ozdemir M, Bambul N. Synthetic marijuana “K2” induced ITP. Platelets. 2014. Apr 21. [Epub ahead of print]
- Tellioglu T. The use of urine drug testing to monitor patients receiving chronic opioid therapy for persistent pain conditions. Medicine and Health, Rhode Island 2008;91(9):279–80, 82.
- Arntson A, Ofsa B, Lancaster D, Simon JR, McMullin M, Logan B. Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens. Journal of analytical toxicology 2013;37(5):284–90. [CrossRef]
- Scheidweiler KB, Huestis MA. Simultaneous quantification of 20 synthetic cannabinoids and 21 metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in human urine by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A 2014;1327:105–17. [CrossRef]
- K2 / Spice Single Test Strip: synthetic cannabinoids drug test. Medical Disposables. Available from: http://www.medicaldisposables.us/synthetic-marijuana-k2-spice-drug-test-strip-p/k2-s.htm?gclid=CPngrqDYvsACFQQQ7AodA3UA2Q.
- Caviness C, Tzilos G, Anderson B, Stein M. Synthetic Cannabinoids: Use and predictors in a Community Sample of Young Adults. Subst Abus. 2014 Sep 15:0. [Epub ahead of print]
- Asicioglu F. New Psycho-Active Substances: The Legal Procedure Used in European Union Countries and Turkey. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2010;20(4):334–9. (Turkish)